Idrugs最新文献

The 2010 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), held in Fort Lauderdale, FL, USA, included topics covering new therapeutic developments in the field of eye and vision research. This conference report highlights selected presentations on the development of FOV-2304 (Fovea Pharmaceuticals SA) for the potential treatment of diabetic macular edema; PHA-666859 (Pfizer Inc) for diabetic retinopathy; GTx-878 (GTx Inc) and FCFD-4514S (Genentech Inc) for age-related macular degeneration; SYL-040012 (Sylentis Sau) for ocular hypertension associated with open-angle glaucoma; PEG-PLA-TNP-470 (Harvard Medical School) for ocular neovascularization; recombinant galectin-3 (Senju Pharmaceutical Co Ltd) for corneal injury; and CellBead Neuro (CellMed Inc) for neurological trauma and neurodegeneration.

SMi's 13th Annual Meeting on Generics, Supergenerics and Patent Strategies, held in London, included topics covering new trends in the generics field, the difficulties faced by companies in entering the generics market and recent developments in IP. This conference report highlights selected presentations on generics in India, protecting pharmaceutical products in China, changes in generics law and litigation in the US and Europe, challenges for market selection and entry for generics companies, the influence of changes in the healthcare market on the generics industry, supergenerics, and biosimilars.

The 2010 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), held in Fort Lauderdale, FL, USA, included topics covering new therapeutic developments in the field of eye and vision research. This conference report highlights selected presentations on the development of OT-440 (Othera Pharmaceuticals Inc) for the potential treatment of glaucoma, an extended-release implant of brimonidine (pSivida Corp) for ocular hypertension, AR-12286 (Aerie Pharmaceuticals Inc) for ocular hypertension or glaucoma, AC-8 (Calmune Corp/RiboVax Biotechnologies SA) for ocular diseases following HSV infection, and fidarestat (Sanwa Kagaku Kenkyusho Co Ltd) and the recombinant proteins NOV and NOVCter (INSERM/University Rene Descartes) for corneal neovascularization.

Medichem--BIT Life Sciences' First Annual International Conference, held in Beijing, included topics covering new developments in the field of medicinal chemistry for drug discovery. This conference report highlights selected presentations on research into the basic biology of signaling, ion channels and natural products; tools and techniques in medicinal chemistry; and medicinal chemistry for developing drugs for neurological, neoplastic and inflammatory diseases. Investigational drugs discussed include TTA-A8 (Merck & Co Inc).

GSK-1605786 (CCX-282; Traficet-EN), a selective antagonist of the CC chemokine receptor (CCR9), is being developed by GlaxoSmithKline plc under license from ChemoCentryx Inc for the potential treatment of inflammatory bowel disease, including Crohn's disease and celiac disease. CCR9 is a tissue-specific lymphocyte trafficking molecule that selectively attracts both B- and T-cells to the small gut. Inhibition of CCR9 by GSK-1605786 may inhibit B- and T-cell entry to the small gut and ameliorate inflammation while leaving immune function at other anatomical sites unaffected. GSK-1605786 was assessed as a treatment for moderate-to-severe Crohn's disease in the phase II/III PROTECT-1 trial and as a treatment for celiac disease in a phase II trial. Data suggest that GSK-1605786 is efficacious in patients with Crohn's disease with the advantage of being orally bioavailable.

The Vaccine Manufacturing--Second Annual visiongain Conference, held in London, included topics covering new technological developments in the field of influenza vaccine research. This conference report highlights selected presentations on influenza vaccine development in mammalian, insect and avian embryonic cells, regulatory considerations for cell culture-based influenza vaccine production, an improved animal model for influenza infection, and considerations for designing vaccine manufacturing facilities. Investigational drugs discussed include FluBiovax (Immunobiology Ltd) and FluBlok (Protein Sciences Corp/UMN Pharma Inc).

The H1N1 Swine Flu: The 2010 Perspective conference, held in New York City, included topics covering new research developments regarding the H1N1 influenza virus. This conference report highlights selected presentations on high-yield reassortant viral production, virus transmission and pathogenesis in ferret and guinea pig models, and the advantages of virus-like particle vaccines. Fatal pathology findings from the 2009 H1N1 strain in New York, and preparedness for and response to the 2009 pandemic, are also discussed.

The 101st Annual Meeting of the American Association of Cancer Research, held in Washington, DC, included topics covering new therapeutic developments in the field of cancer research. This conference report highlights selected presentations on preclinical data on the novel pan-PI3K pyrimidine-derived inhibitor BKM-120 (Novartis AG), the dual inhibition of mTOR/PI3K in NSCLC by PF-4691502 (Pfizer Inc), the small-molecule PDK-1 inhibitors PF-05177624 and PF-05197281 (both Pfizer) and the ability of RO-5323441 (F Hoffmann-La Roche Ltd/ThromboGenics NV/BioInvent International AB) to block tumor growth in vivo. Phase I clinical trial results for VB-111 (VBL Therapeutics) are also presented.

SMi's sixth annual conference on Asthma & COPD, held in London, included topics covering new therapeutic developments in the field of asthma and COPD. This conference report highlights selected presentations on understanding these diseases; bronchodilators and corticosteroids, both of which remain a mainstay in asthma therapy; new developments in COPD therapy; PI3K inhibitors as a new treatment approach for asthma and COPD; and oligonucleotides, particularly DNAzyme therapy for asthma.